Oracle buying drug trials software maker for $US685 million

The deal will strengthen Oracle's hand in health care tech

Oracle on Friday announced plans to buy Phase Forward, which develops software for drug manufacturers, for about $US685 million. The deal is expected to close mid-year.

Phase Forward's SaaS (software as a service) products guide the entire drug-development process, from clinical trials to monitoring after they receive regulatory approval, according to a statement. Its employees will be folded into Oracle's Health Sciences global business unit.

The acquisition is just the latest in a long string by Oracle in recent years, but also one of the larger ones in recent history. It ties into the vendor's desire to mine new business from vertical markets like health care.

The market is particularly attractive these days, given factors like the recently approved U.S. health care reform legislation.In buying Phase Forward, "[Oracle gets] something unique," said Ray Wang, partner with analyst firm Altimeter Group. "It's smack in the heart of medical research, smack in the heart of all the public sector dollars."

The pending acquisition follows Oracle's purchase last year of Relsys, maker of drug-safety software and a Phase Forward competitor. Also last year, Oracle bought intellectual-property assets from Conformia, which developed technology for managing the design and development of pharmaceuticals. Apart from selling specialized applications, Oracle's industry strategy is meant to give it a chance to sell companies other products, such as middleware, databases and now hardware, said Forrester Research analyst Paul Hamerman.

Moreover, Phase Forward's roughly 335 customers include many large pharmaceuticals, "which happen to be SAP shops for the most part," Hamerman said.

Phase Forward also counts users among government organizations, biotech firms and medical device makers.

Oracle is far from finished buying health-related companies, Hamerman added. "This is a relatively new business unit," he said. "If you look at the entire health care ecosystem, that's huge. Another way they may want to play is on the health care provider side."

Meanwhile, the announcement underscores a second storyline playing out at Oracle: Its gradual move toward on-demand software.

"The thing you'll find about Oracle is that within the next 24 months, almost every new product they deliver is going to be SaaS," Wang said.

Keep up with the latest tech news, reviews and previews by subscribing to the Good Gear Guide newsletter.

Chris Kanaracus

IDG News Service
Topics: independent software developer, Oracle, Mergers and acquisitions
Comments are now closed.

Latest News Articles

Most Popular Articles

Follow Us

GGG Evaluation Team

Kathy Cassidy

STYLISTIC Q702

First impression on unpacking the Q702 test unit was the solid feel and clean, minimalist styling.

Anthony Grifoni

STYLISTIC Q572

For work use, Microsoft Word and Excel programs pre-installed on the device are adequate for preparing short documents.

Steph Mundell

LIFEBOOK UH574

The Fujitsu LifeBook UH574 allowed for great mobility without being obnoxiously heavy or clunky. Its twelve hours of battery life did not disappoint.

Andrew Mitsi

STYLISTIC Q702

The screen was particularly good. It is bright and visible from most angles, however heat is an issue, particularly around the Windows button on the front, and on the back where the battery housing is located.

Simon Harriott

STYLISTIC Q702

My first impression after unboxing the Q702 is that it is a nice looking unit. Styling is somewhat minimalist but very effective. The tablet part, once detached, has a nice weight, and no buttons or switches are located in awkward or intrusive positions.

Resources

Best Deals on GoodGearGuide

Compare & Save

Deals powered by WhistleOut
WhistleOut

Latest Jobs

Don’t have an account? Sign up here

Don't have an account? Sign up now

Forgot password?